NAc Proteomic Signatures and Antidepressant Response: Insights from Rat Models

Distinct Nucleus Accumbens Proteomic Profiles Predict Stress and Antidepressant Outcomes in Rats

A September 2026 preclinical study published via OpenAlex (source) demonstrates that specific proteomic signatures in the nucleus accumbens (NAc) are associated with stress vulnerability and antidepressant response in two well-characterized rat strains, Wistar and Kyoto. The research found that Kyoto rats, which are known for heightened stress sensitivity and depressive-like behaviors, exhibit unique NAc molecular profiles both at baseline and after chronic mild stress (CMS) exposure, compared to Wistar rats. These molecular differences correlated with behavioral phenotypes and differential responses to the antidepressant venlafaxine, suggesting that individual molecular signatures in the NAc may underlie treatment-resistant depression.

Molecular Mechanisms: Mitochondrial Stress, Synaptic Signaling, and Strain-Specific Pathways

Proteomic analysis using high-resolution data-independent acquisition mass spectrometry revealed that Kyoto rats displayed baseline enrichment in NAc metabolic pathways, including alterations in Ogdhl and Nit2 proteins. Following CMS, Kyoto rats showed increased mitochondrial protein degradation and oxidative stress pathway enrichment, alongside decreased synaptic signaling proteins such as Ppp1r1b/DARPP-32. These molecular changes paralleled early-onset anhedonia, social withdrawal, and blunted glucocorticoid output—hallmarks of stress vulnerability. In contrast, Wistar rats exhibited more resilient behavioral and molecular profiles, with venlafaxine reversing most stress-induced alterations.

Notably, venlafaxine failed to improve anhedonia in Kyoto rats and even exacerbated aggressive behaviors, while further enriching NAc pathways related to bioenergetics, transmembrane transport, and astrocyte activation. These findings underscore that the same pharmacological intervention can produce divergent molecular and behavioral outcomes depending on pre-existing neurobiological context—a critical insight for understanding treatment heterogeneity in depression.

Implications for Precision Pharmacology and Psychedelic Research

The identification of strain-specific NAc proteomic signatures offers a potential roadmap for developing precision pharmacological approaches to depression. While the study did not examine psychedelic compounds directly, the findings are relevant for the field: both classic antidepressants and psychedelics are believed to modulate synaptic plasticity and neurocircuitry in mood-related brain regions, including the NAc. The observed molecular heterogeneity suggests that individual differences in NAc proteomic architecture could influence response to a wide range of therapeutics, including emerging psychedelic-assisted interventions.

This study also highlights a key challenge for clinical translation: animal models with distinct genetic and behavioral backgrounds can manifest dramatically different responses to the same drug. For psychedelic researchers and developers, this underscores the importance of stratifying clinical trial participants by relevant biological markers—such as proteomic or transcriptomic signatures—rather than relying solely on symptom-based diagnoses. A non-obvious implication is that preclinical failures to replicate antidepressant effects in certain rodent strains may reflect real-world heterogeneity in human populations, rather than flaws in the compounds themselves.

Risks, Limitations, and Unknowns

While the study provides valuable mechanistic insights, several limitations temper its immediate translational impact. The research was conducted exclusively in male rats, leaving open questions about sex differences—a known factor in depression epidemiology and treatment response. The focus on venlafaxine (a serotonin-norepinephrine reuptake inhibitor) limits generalizability to other antidepressant classes, including serotonergic psychedelics. Additionally, the functional roles of many identified proteins require further validation, and it remains unclear how closely these rodent NAc signatures map onto human neurobiology.

For policy and regulatory stakeholders, the study does not address legal or access issues, nor does it provide direct evidence for the efficacy or safety of psychedelic compounds. However, it does reinforce the need for biomarker-driven clinical trial designs and post-market surveillance strategies that account for individual variability in molecular and behavioral responses.

Looking Ahead: Toward Biomarker-Guided Depression Therapies

Future research should prioritize cross-species validation of NAc proteomic signatures, inclusion of both sexes, and expansion to diverse pharmacological agents—including psychedelics. As the field moves toward precision psychiatry, integrating molecular profiling into both preclinical and clinical studies could help identify which patients are most likely to benefit from specific interventions, and which may be at risk for adverse or paradoxical effects. This approach may also facilitate the discovery of novel therapeutic targets for treatment-resistant depression, a major unmet need in mental health care.

How we research / reviewed by Dr. Alex M. Carter, PhD (Neurobiology), on 2026-09-02. Sources: OpenAlex, original study authors, and direct review of study methodology.